Good results seen in early-stage intravitreal gene therapy trial for wet AMD

Intravitreal 4D-150 demonstrated positive interim results for the treatment of wet age-related macular degeneration in a phase 1/2 trial, according to a press release from 4D Molecular Therapeutics.
In the phase 1 dose-exploration stage of the phase 1/2 PRISM clinical trial, five patients received a dose of 3E10 vg per eye of the dual-transgene intravitreal gene therapy, five received 1E10 vg per eye and five received 6E9 vg per eye.
The dose was well tolerated by all patients at 24 weeks, and 14 patients experienced no inflammation after treatment. There were no reports of serious adverse

Intravitreal 4D-150 demonstrated positive interim results for the treatment of wet age-related macular degeneration in a phase 1/2 trial, according to a press release from 4D Molecular Therapeutics.
In the phase 1 dose-exploration stage of the phase 1/2 PRISM clinical trial, five patients received a dose of 3E10 vg per eye of the dual-transgene intravitreal gene therapy, five received 1E10 vg per eye and five received 6E9 vg per eye.
The dose was well tolerated by all patients at 24 weeks, and 14 patients experienced no inflammation after treatment. There were no reports of serious adverse